LOGIN  |  REGISTER
Viking Therapeutics

DocGo to Announce First Quarter 2023 Results on Monday, May 8th

April 25, 2023 | Last Trade: US$1.32 0.05 3.54
  • Management to host investor conference call and webcast at 5:00pm EDT on that day

NEW YORK / Apr 25, 2023 / Business Wire / DocGo, a leading provider of last-mile mobile health services (Nasdaq: DCGO), today announced that the company will report results for the first quarter ended March 31, 2023, after the markets close on Monday, May 8th. Management will host a conference call for analysts and investors at 5:00pm ET on that day.

Conference call and webcast details:
Monday, May 8th, 5:00pm EDT
1-877-407-0784 (U.S.)
1-201-689-8560 (international)
Conference ID: 13737381
To access the Call me™ feature, which avoids the need to wait for an operator, click here.
The webcast can be accessed under Events on the Investors section of the company’s website, https://ir.docgo.com/.

About DocGo

DocGo is a leading provider of last-mile mobile care services. DocGo is disrupting the traditional four-wall healthcare system by providing high quality, highly affordable care to patients where and when they need it. DocGo's innovative technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.

Recursion

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page